Seres Therapeutics Dirección

Dirección controles de criterios 3/4

El CEO de Seres Therapeutics' es Eric Shaff , nombrado en Jan 2019, tiene una permanencia de 5.25 años. compensación anual total es $3.16M, compuesta por 21.7% salario y 78.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.09% de las acciones de la empresa, por valor de $84.52K. La antigüedad media del equipo directivo y de la junta directiva es de 4.6 años y 7.6 años, respectivamente.

Información clave

Eric Shaff

Chief Executive Officer (CEO)

US$3.2m

Compensación total

Porcentaje del salario del CEO	21.7%
Permanencia del CEO	5.3yrs
Participación del CEO	0.09%
Permanencia media de la dirección	4.6yrs
Promedio de permanencia en la Junta Directiva	7.6yrs

Actualizaciones recientes de la dirección

Recent updates

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Mar 23

Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns

Jan 30

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Dec 18

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Aug 31

Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 02

Rock star Growth Puts Seres Therapeutics (NASDAQ:MCRB) In A Position To Use Debt

Dec 27

Seres Therapeutics Molecular Data On SER-109 Looks Good

Oct 04

Seres Therapeutics: Here We Go Again

Sep 09

Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Sep 03

Need To Know: Analysts Are Much More Bullish On Seres Therapeutics, Inc. (NASDAQ:MCRB) Revenues

Jul 03

Seres Therapeutics (MCRB) Presents At 2021 Jefferies Virtual Healthcare Conference - Slideshow

Jun 08

Seres Therapeutics gets FDA clearance for SER-155 IND trials

Jun 01

Broker Revenue Forecasts For Seres Therapeutics, Inc. (NASDAQ:MCRB) Are Surging Higher

May 20

Seres Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 05

Is Seres Therapeutics (NASDAQ:MCRB) Using Debt In A Risky Way?

Apr 05

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Eric Shaff en comparación con los beneficios de Seres Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$3m	US$685k	-US$114m
Sep 30 2023	n/a	n/a	-US$141m
Jun 30 2023	n/a	n/a	-US$153m
Mar 31 2023	n/a	n/a	-US$265m
Dec 31 2022	US$4m	US$662k	-US$250m
Sep 30 2022	n/a	n/a	-US$231m
Jun 30 2022	n/a	n/a	-US$103m
Mar 31 2022	n/a	n/a	-US$87m
Dec 31 2021	US$10m	US$625k	-US$66m
Sep 30 2021	n/a	n/a	-US$34m
Jun 30 2021	n/a	n/a	-US$132m
Mar 31 2021	n/a	n/a	-US$105m
Dec 31 2020	US$3m	US$590k	-US$89m
Sep 30 2020	n/a	n/a	-US$90m
Jun 30 2020	n/a	n/a	-US$76m
Mar 31 2020	n/a	n/a	-US$66m
Dec 31 2019	US$2m	US$540k	-US$70m
Sep 30 2019	n/a	n/a	-US$73m
Jun 30 2019	n/a	n/a	-US$78m
Mar 31 2019	n/a	n/a	-US$95m
Dec 31 2018	US$1m	US$435k	-US$99m
Sep 30 2018	n/a	n/a	-US$107m
Jun 30 2018	n/a	n/a	-US$92m
Mar 31 2018	n/a	n/a	-US$92m
Dec 31 2017	US$2m	US$377k	-US$89m

Compensación vs. Mercado: La compensación total de Eric($USD3.16M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD677.87K).

Compensación vs. Ingresos: La compensación de Eric ha sido consistente con los resultados de la empresa en el último año.

CEO

Eric Shaff (47 yo)

5.3yrs

Permanencia

US$3,158,336

Compensación

Mr. Eric D. Shaff, M.B.A., serves as President and Chief Executive Officer at Seres Therapeutics, Inc. since January 15, 2019 and serves as its Director since January 2019. He served as Chief Operating Off...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Eric Shaff	President	5.3yrs	US$3.16m	0.090% $ 111.6k
Lisa von Moltke	Executive VP & Chief Medical Officer	4.1yrs	US$1.57m	0.011% $ 14.0k
Teresa Young	Executive VP and Chief Commercial & Strategy Officer	3.8yrs	US$1.82m	0.010% $ 13.0k
Marella Thorell	Executive VP & CFO	less than a year	sin datos	sin datos
David Ege	Executive VP & Chief Technology Officer	3.5yrs	US$5.32m	0.049% $ 60.9k
Matthew Henn	Executive VP & Chief Scientific Officer	5.2yrs	US$1.67m	0.042% $ 52.3k
Carlo Tanzi	Investor Relations Officer	8.4yrs	sin datos	sin datos
Thomas DesRosier	Chief Legal Officer	7.9yrs	US$1.44m	0.080% $ 99.5k
Caroline Holda	Assistant General Counsel	no data	sin datos	sin datos

4.6yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de MCRB se considera experimentado (4.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Eric Shaff	President	5.3yrs	US$3.16m	0.090% $ 111.6k
Willard Dere	Independent Director	6.8yrs	US$166.81k	0.021% $ 26.2k
Dennis Ausiello	Independent Director	9yrs	US$222.27k	0.15% $ 184.0k
Kurt Graves	Independent Director	8.4yrs	US$219.23k	0.12% $ 146.8k
Richard Kender	Independent Director	9.5yrs	US$174.57k	0.042% $ 52.4k
Mark Wilcox	Member of Scientific Advisory Board	9.3yrs	sin datos	sin datos
Andrew Goodman	Member of Scientific Advisory Board	no data	sin datos	sin datos
Curtis Huttenhower	Member of Scientific Advisory Board	no data	sin datos	sin datos
Paul Biondi	Independent Director	4.1yrs	US$211.73k	0.032% $ 39.3k
Stephen Berenson	Independent Chairman	4.7yrs	US$249.23k	0.0024% $ 3.0k
Robert Jenq	Member of Scientific Advisory Board	no data	sin datos	sin datos
Elhanan Borenstein	Member of Scientific Advisory Board	no data	sin datos	sin datos

7.6yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de MCRB se considera experimentada (7.6 años de antigüedad promedio).

Seres Therapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Seres Therapeutics Appoints Marella Thorell as Executive Vice President

Insufficient new directors

Seres Therapeutics, Inc. Announces the Appointment of Claire M. Fraser, Ph.D., to Its Board of Directors

Seres Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer

Recent updates

Seres Therapeutics Receives Non-Compliance Letter from The Nasdaq Stock Market LLC Related to Nasdaq Listing Rule 5450(a)(1)

New minor risk - Market cap size

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Consensus revenue estimates decrease by 63%, EPS upgraded

New minor risk - Financial position

Full year 2023 earnings: EPS exceeds analyst expectations

No longer forecast to breakeven

Seres Therapeutics Appoints Marella Thorell as Executive Vice President

Price target increased by 7.7% to US$9.02

Price target increased by 15% to US$9.80

Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

Forecast to breakeven in 2026

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Consensus EPS estimates upgraded to US$0.98 loss, revenue downgraded

Price target decreased by 13% to US$8.54

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Seres Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Share price stability

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Consensus EPS estimates fall by 34%

Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?

Second quarter 2023 earnings: EPS misses analyst expectations

Second quarter 2023 earnings: EPS misses analyst expectations

Price target decreased by 7.6% to US$10.17

Seres Therapeutics, Inc. and Nestle Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023

Seres Therapeutics, Inc. and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™

Consensus EPS estimates upgraded to US$0.96 loss

Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome

First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.61 loss in 1Q 2022)

Consensus estimates of losses per share improve by 13%

Price target decreased by 11% to US$11.00

Full year 2022 earnings: EPS and revenues miss analyst expectations

Seres Therapeutics' Investigational Ser-109 Ecospor Iv Study Data Publishes in Jama Network Open

Seres Therapeutics, Inc. Announces Initiation of Enrollment in SER-155 Phase 1B Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Insufficient new directors

Seres Therapeutics, Inc. Announces the Appointment of Claire M. Fraser, Ph.D., to Its Board of Directors

Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Consensus forecasts updated

Price target increased to US$14.33

Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review

Seres Therapeutics, Inc. Announces the Publication of Phase 3 Clinical Data in the Journal of the American Medical Association

Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection

Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)

Seres Therapeutics: What The Market Is Missing

Consensus revenue estimates increase by 16%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Seres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22M

Seres Therapeutics: The Good And The Challenging

Seres Therapeutics stock slips on $100M stock offering

Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?

Seres Therapeutics: As Biotech Fades The Case For Seres Investment Strengthens

Seres Therapeutics, Inc. Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection

Seres Therapeutics Presents Phase III Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting

Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic Ser-109 for Recurrent C. Difficile Infection At the Digestive Disease Week (Ddw) Annual Meeting

Consensus revenue estimates fall by 64%

Price target decreased to US$17.57

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Seres Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

Consensus revenue estimates fall by 30%

Seres Therapeutics Is Playing A Long Game

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates

Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer

Seres Therapeutics, Inc. Announces the Publication in the New England Journal of Medicine of Data from Its Phase 3 ECOSPOR III study evaluating SER-109

Rock star Growth Puts Seres Therapeutics (NASDAQ:MCRB) In A Position To Use Debt

Seres Therapeutics, Inc. Announces Preliminary SER-287 Phase 2b ECO-RESET Study Microbiome Data Analysis

Seres Therapeutics Announces First Patient Enrolled in Phase 1B Study of SER-155

Price target decreased to US$19.13